Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2012 Jul 19;7(7):e41268. doi: 10.1371/journal.pone.0041268

Acyl Coenzyme A Synthetase Long-Chain 1 (ACSL1) Gene Polymorphism (rs6552828) and Elite Endurance Athletic Status: A Replication Study

Thomas Yvert 1,#, Zi-Hong He 2,#, Catalina Santiago 1, Yang Hu 3, Yan-Chun Li 3, Félix Gómez-Gallego 1, Carmen Fiuza-Luces 1, Zoraida Verde 1, Carlos A Muniesa 4, Jesús Oliván 4, Alfredo Santalla 5, Jonatan R Ruiz 6,7, Alejandro Lucia 1,*
Editor: Nuria Garatachea8
PMCID: PMC3400600  PMID: 22829935

Abstract

The aim of this study was to determine the association between the rs6552828 polymorphism in acyl coenzyme A synthetase (ACSL1) and elite endurance athletic status. We studied 82 Caucasian (Spanish) World/Olympic-class endurance male athletes, and a group of sex and ethnically matched healthy young adults (controls, n = 197). The analyses were replicated in a cohort of a different ethnic origin (Chinese of the Han ethnic group), composed of elite endurance athletes (runners) [cases, n = 241 (128 male)] and healthy sedentary adults [controls, n = 504 (267 male)]. In the Spanish cohort, genotype (P = 0.591) and minor allele (A) frequencies were similar in cases and controls (P = 0.978). In the Chinese cohort, genotype (P = 0.973) and minor allele (G) frequencies were comparable in female endurance athletes and sedentary controls (P = 0.881), whereas in males the frequency of the G allele was higher in endurance athletes (0.40) compared with their controls (0.32, P = 0.040). The odds ratio (95%CI) for an elite endurance Chinese athlete to carry the G allele compared with ethnically matched controls was 1.381 (1.015–1.880) (P-value = 0.04). Our findings suggest that the ACSL1 gene polymorphism rs6552828 is not associated with elite endurance athletic status in Caucasians, yet a marginal association seems to exist for the Chinese (Han) male population.

Introduction

Elite athletic status is a complex phenotype, with several genetic polymorphisms, many of which remain to be identified, contributing to athletic success, whether individually or in combination with other polymorphisms [1]. Genome-wide association (GWA) can help identifying novel candidate polymorphisms associated with elite endurance status. This type of studies evaluates association of genetic variation with outcomes or traits of interest by using 100,000 to 1 million or more markers across the genome without any previous hypotheses about potential mechanisms [2]. A GWA study was recently conducted by Bouchard et al. [3] in sedentary Caucasians to study the association of 324,611 single-nucleotide polymorphisms (SNPs) and the trainability of one of the main phenotype traits indicative of human endurance performance, i.e. maximal oxygen uptake (VO2max). The strongest association with the training response of VO2max was found to acyl coenzyme A synthetase long-chain 1 (ACSL1) gene polymorphism (rs6552828). The ACSL1 gene is a candidate to explain individual variability in endurance performance, as well as in some health-related phenotypes, owing to its potential role in aerobic metabolism at the adypocite, cardiomyocite, liver and skeletal muscle fiber level [4], [5], [6], [7], [8], [9].

The findings of GWA studies should be further explored in genetic association studies focused on those SNPs showing the highest level of association [2]. Thus, the purpose of the present case:control study was to determine the association between the ACSL1 rs6552828 polymorphism and elite endurance athletic status. To this end, we studied a cohort that comprised Caucasian (Spanish) World/Olympic-class endurance male athletes (cases), and sex and ethnically-matched healthy young adults (controls). We also studied a replication cohort of a different ethnic origin (Chinese of the Han ethnic group), composed of elite endurance athletes (cases), and healthy sedentary adults (controls). Owing to the important putative role of ACSL1 in aerobic-related phenotypes [4], [5], [6], [7], [8], [9] we hypothesized that the ACSL1 rs6552828 polymorphism is associated with elite endurance athletic status.

Methods

Participants

The research project was in accordance with the Declaration of Helsinki, it was approved by the corresponding University Review Boards [Universidad Europea de Madrid (UEM), Spain and China Institute of Sport Science (Beijing, China)]. Written consent was obtained from each participant. Our study adhered to most of the recent guidelines for STrengthening the REporting of Genetic Association studies (STREGA), including issues such as replication, selection of participants, rationale for choice of genes and variants, statistical methods or relatedness [10].

Spanish cohort

The population [n = 383, all unrelated Spanish (Caucasian for ≥3 generations) healthy males] originally comprised:

  1. 93 endurance elite athletes aged 19–39 years (cases). This sample included 22 elite endurance runners (mostly 5,000–10,000 m specialists). All had participated at least twice in previous Olympiads and 11 of them were medallists in previous World or Europe Championships. Their mean±SD VO2max was 78.0±1.7 ml·kg−1·min−1 (range: 69, 87). The sample also included 32 professional road cyclists who were all Tour de France finishers, included three top-3 finishers in this race and several stage winners in the three main tour races (Tour, Giro, Vuelta). Their mean±SD maximal oxygen uptake (VO2max) was 74.5±1.7 ml·kg−1·min−1 (62, 86). The endurance athletic cohort also comprised 39 rowers [VO2max: 71.7±0.8 ml·kg−1·min−1 (58, 87) or 5.2±0.1 L·min−1 (4.2, 6.0)] who were among the best in the World, i.e. each had won ≥ one bronze, silver or gold medal in the lightweight category (skip or scull, including a total of 6 gold medals) in the World Championships held during 1997–2006. The mean VO2max of the whole athletic cohort was 73.7±6.4 ml·kg−1·min−1.

  2. 197 healthy, non-athletic controls aged 19–32 years (VO2max: 50.2±0.3 ml·kg−1·min−1). All were undergraduate Physical Education students from the same university (UEM). Inclusion and exclusion criteria for this group were to be free of any diagnosed cardiorespiratory disease and not to be engaged in competitive sports or in formal, supervised exercise training (i.e. performing less than 3 structured weekly sessions of strenuous exercise as running, swimming, bicycling, and weight lifting) or to have a family history of competitive sports participation.

The VO2max values of runners, cyclists and rowers were obtained using a breath-by-breath system (Oxycon Pro System, Jaeger, Wuerzburg, Germany) in laboratory treadmill, cycle-ergometer or rower-ergometer tests performed until volitional exhaustion. The VO2max of controls was estimated from the time to complete 2,000 meter tests [11]; the tests were performed inside a 400-meter outdoor track under similar environmental conditions (temperature, ∼23–24°C; relative humidity, 45–55%; barometric pressure, ∼720 mmHg).

Replication cohort

The population [n = 751, men and women, all unrelated of Chinese descent (Han origin) for ≥3 generations] comprised:

  1. 246 (131 men, 115 women) unrelated elite endurance runners aged 19 to 37 years. They were the best Chinese runners in middle-distance (1,500 m) (n = 18, 10 men, 8 women) 3,000 to 10,000 m track events (n = 164; 90 men, 74 women) and marathon in the last years (n = 64; 31 men, 33 women), including World record holders, and most of whom had participated in at least one World-championship or Olympiad.

  2. 505 (267 men, 238 women) healthy unrelated control participants aged 19 to 23 years [non-athletic undergraduate students from the China Agricultural University (Beijing) with no self-reported history (or family history) of competitive sports participation].

Genotyping

Our study followed recent recommendations for replicating genotype-phenotype association studies [12]: genotyping was performed specifically for research purposes, and the researchers in charge of genotyping were totally blinded to the participants' identities [DNA samples were tracked solely with bar-coding and personal identities were only made available to the main study researcher (in Spain or China) who was not involved in actual genotyping].

Spanish cohort

We obtained DNA from participants' blood or saliva samples over years 2004–2008 and used the classical phenol-chloroform DNA extraction protocol with alcoholic precipitation. Genomic DNA was resuspended in 50 µl milli-Q H2O and stored at −20°C. Genotyping was performed during April–May 2011 in the Genetics laboratory of the UEM. Polymerase chain reaction (PCR) amplification was performed using a StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA). Allelic discrimination analysis for the ACSL1 rs6552828 polymorphism was performed with predesigned Applied Biosystems TaqMan® SNP Genotyping Assays on demand (Assay ID: C__30469648_10).

Replication cohort

We obtained samples of peripheral whole blood from elite athletes (during years 2003 and 2004, and 2009–2010) and controls (2004 and 2011) and extracted genomic DNA using a Wizard Genomic DNA Purification Kit (Promega, Madison, Wisconsin, USA). Genotype analyses were performed during June–July 2011 in the Science and Research Centre of the Beijing Sports University (Beijing, China).

For high-throughput genotyping of the ACSL1 rs6552828 polymorphism, we used a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) platform (Sequenom, San Diego, CA, USA). Primers for PCR and single base extension were designed by using the Assay Designer software package (Sequenom, San Diego, CA, USA). The DNA sample was diluted to 5 ng/µl, and 1 µl of DNA was combined with 0.95 µl of water, 0.625 µl of PCR buffer containing 15 mM MgCl2, 1 µl of 2.5 mM dNTP, 0.325 ul of 25 mM MgCl2, 1 µl of PCR primers and 0.1 µl of 5units/µl HotStar Taq (Qiagen, Düsseldorf, Germany). The PCR conditions were as follows: 94°C for 15 min followed by 45 cycles at 94°C 20 s, 56°C 30 s, and 72°C 1 min, and a final incubation at 72°C 3 min. After PCR amplification, the remaining dNTPs were dephosphorylated by adding1.53 µl of water, 0.17 µl of Shrimp Alkaline Phosphatase (SAP) buffer, and 0.3 units of SAP (Sequenom, San Diego, CA, USA). The reaction was placed at 37°C for 40 min, and the enzyme was deactivated by incubation at 85°C for 5 min. Thereafter, the single base extension (SBE) over the SNP was combined with 0.755 µl of water, 0.2 µl of 10X iPLEX buffer (Sequenom, San Diego, CA, USA), 0.2 µl of termination mix, 0.041 µl of iPLEX enzyme (Sequenom, San Diego, CA, USA), and 0.804 µl of 10 µM extension primer. The SBE conditions were as follows: 94°C 30 s, 94°C 5 s, 5 cycles at 52°C for 5 s, 40 cycles at 80°C for 5 s, and final extension at 72°C for 3 min. The reaction mix was desalted by adding 6 mg of cation exchange resin (Sequenom, San Diego, CA, USA), mixed and resuspended in 25 µl of water. The completed genotyping reactions were spotted onto a 384 well Spectro Chip using a MassARRAY® Nanodispenser and determined by a matrix-assisted laser desorption ionization time-of-flight mass spectrometer (Sequenom, San Diego, CA, USA). Genotype calling was performed in real time with MassARRAY® RT software (version 3.0.0.4) and analyzed using the Massarray Typer software, version 3.4 (Sequenom, San Diego, CA, USA).

Statistical analysis

Genotypic and allele frequencies were compared among sedentary controls and endurance athletes using the χ2 test. We used logistic regression analysis to analyse the association of the ACSL1 rs6552828 polymorphism with elite endurance athletic status. The analyses were conducted in Spanish and Chinese separately, and in the case of the Chinese population, the analyses were conducted separately for men and women. All statistical analyses were performed using the PASW (v. 18.0 for WINDOWS, Chicago) and the α was set at 0.05.

Results

Spanish cohort

There were no failures in sample collection, DNA acquisition or genotyping procedures, except for 11 athletes, for which the amount of DNA gathered from saliva was insufficient to allow ACSL1 rs6552828 genotype assessment. Genotype distributions met Hardy-Weinberg equilibrium (HWE) in both controls and athletes (Table 1). Genotype (P = 0.591) and minor allele (A) frequencies were similar in sedentary controls and athletes (P = 0.978). The odds ratio (OR) and 95% confidence interval (95%CI) for the association between carriage of the A allele of the ACSL1 rs6552828 polymorphism and athletic status was 0.997 (0.819–1.214).

Table 1. Genotype frequencies [n(%)] of ACSL1 rs6552828 polymorphism in Spanish controls (n = 197) and elite endurance athletes (n = 82).

Controls Endurance
AA 25 (12.7%) 14 (17.1%)
AG 98 (49.7%) 37 (45.1%)
GG 74 (37.6%) 31 (37.8%)
MAF 0.37 0.39
HWE 0.395 0.605

MAF, minor allele frequency (A); HWE, Hardy Weinberg Equilibrium.

Genotype: χ2 = 1.052, P = 0.591; Allele: χ2 = 0.001, P = 0.978.

Replication cohort

There were no failures in sample collection, DNA acquisition or genotyping procedures, except for 1 participant (female) in the control group, and 5 (3 male, 2 female) in the athlete's group. Genotype distributions were in HWE except for male endurance athletes (P = 0.035, Table 2). In females, genotypic (P = 0.973) and allele frequencies (P = 0.881) were similar in endurance and controls, whereas in males both genotypic (P = 0.019) and allelic (P = 0.040) differed in endurance and controls. The odds ratio (95%CI) for an elite endurance Chinese athlete of having the G allele compared with ethnically-matched controls was 0.975 (0.697–1.364, P = 0.881) for females, whereas in males, the odds ratio of having the G allele was 1.381 (1.015–1.880, P = 0.04).

Table 2. Genotype frequencies [n(%)] of ACSL1 rs6552828 polymorphism in Chinese controls (n = 504, 267 men, 237 women) and elite endurance athletes (n = 241, 128 men, 113 women).

Controls Endurance
Males
AA 122 (45.7%) 40 (31.3%)
AG 115 (43.1%) 73 (57.0%)
GG 30 (11.2%) 15 (11.7%)
MAF 0.32 0.40
HWE 0.712 0.035
Females
AA 102 (43.0) 49 (43.4)
AG 110 (46.4) 53 (46.9)
GG 25 (10.5) 11 (9.7)
MAF 0.33 0.33
HWE 0.560 0.539

MAF, minor allele frequency (G); HWE, Hardy Weinberg Equilibrium.

Males: Genotype: χ2 = 7.961, P = 0.019; Allele: χ2 = 4.226, P = 0.040.

Females: Genotype: χ2 = 0.055, P = 0.973; Allele: χ2 = 0.022, P = 0.881.

Discussion

The main finding of our study was that the ACSL1 rs6552828 SNP, located in the first intron of the ACSL1 gene, 715 bp and 718 bp upstream of exon 2 and the start codon, respectively, was not associated with elite endurance athletic status in Spanish men, yet a marginal association was found in Chinese men. The ACSL1 gene is a putative candidate to explain individual variability in endurance performance, as well as in some health related phenotypes, owing to its potential role in aerobic metabolic adaptations to regular exercise, at the adypocite, cardiomyocite, liver and skeletal muscle fiber level. Long-chain acyl coenzyme A (acyl-CoA) synthetase (ACSL) isoenzymes, of which ACSL1 is the main and most studied isoenzyme convert free fatty acids (FFA) to acyl coenzyme A (acyl-CoA) in an ATP-dependent manner, simultaneously activating and trapping FFA within cells [13]. Activation of FFA to acyl-CoA is required before FFAs can be oxidized to provide ATP. ACSL1 is highly expressed in major energy-metabolizing tissues such as fat, liver, and skeletal muscles [5], [6]. Recent research also supports evidence for an important role of ACSL1 in heart metabolism [14].

The role of ACSL1 in FFA oxidation in different tissues has been shown using transgenic mice models. Mice lacking ACSL1 specifically in adipose tissue have defects in adipose FFA oxidation [9], whereas those unable to express ACSL1 in heart ventricles show compensatory catabolism of glucose and amino acids leading to mTOR activation and cardiac hypertrophy without lipid accumulation or dysfunction [14]. In contrast, mice overexpressing ACSL1 specifically at the heart level show markedly impaired metabolic homeostasis with accumulation of triglycerides and phospholipids [15].

ACSL1 is a candidate to explain individual differences in some several disease and endurance exercise-related phenotypes. Recent research has shown that the ACSL1 rs9997745 polymorphism influences the risk of metabolic disease, most likely via disturbances in FFA metabolism [16]; no individual or combined association was however found for other SNPs of this gene, i.e. rs4862417, rs13120078, rs12503643 and the one we studied here, rs6552828. A GWA study recently conducted by Bouchard et al. [3] on 324,611 SNPs identified a set of 21 SNPs accounting for 49% of the variance in the trainability of VO2max [3]. The strongest association with the training response of VO2max was found to ACSL1 rs6552828. In the single-SNP analyses, rs6552828 explained 6.1% of the variance in the response of VO2max. Homozygotes of the rs6552828 minor allele (AA) had 125 mL/min (−28%) and 63 mL/min (−17%) lower VO2max response than the common allele homozygotes (GG) and the heterozygotes (AG) respectively. Interestingly, in our study the A allele was less frequent in elite male endurance Chinese athletes compared with their controls. It must be also kept in mind that the A allele was the major allele in the Chinese cohort, which highlights inter-ethnic differences in genotype distributions.

To our knowledge, there is no functional data on the rs6552828 SNP; thus, we can only speculate about mechanisms underlying our findings. The intronic location of this SNP has the potential to affect mRNA stability or to modulate ACSL1 gene transcriptional activity. Indeed, non-coding SNPs could regulate the alternative splicing of mRNA leading to changes in gene expression [17] and phenotype traits [18], [19]. Non-coding SNPs can also influence the binding of transcription factors [20]. Another possibility is that the ACSL1 is part of the group of candidate genes, among which are calcineurin genes [21], but many of which are yet to be identified, whose cumulative effect explains, at least partly, individual variations in endurance performance in the Chinese Han population. It could also be possible that the rs6552828 SNP may be a surrogate marker for other functional ACSL1 SNPs in the region.

We believe the results of our study are overall valid, as all the following criteria were met [2]: cases clearly presented the main study phenotype (i.e. being an elite athlete), as we studied some of the best elite endurance athletes world-wide, participants within both cohorts were ethnically-matched, genetic assessment was accurate and unbiased, genotype distributions were in HWE in the control group of the two cohorts, and we used a replication cohort of a different ethnic origin. Current body of knowledge on genetic factors associated with exercise phenotypes and athletic status comes mainly from research performed on Caucasian populations. Further investigations are thus needed with other ethnic groups and populations as the one studied here, i.e. representing an important fraction of the total planet population.

In summary, our findings suggest that the ACSL1 gene polymorphism rs6552828 is marginally associated with male elite endurance status in Chinese (Han) population yet such association was not found in Chinese females or in a different (Caucasian) cohort. Our findings exemplify the need for further genetic association studies in the field of sport sciences to use at least two cohorts of a different ethnic background in order to increase the generalisability of their results.

Footnotes

Competing Interests: Co-authors Alejandro Lucia and Jonatan R. Ruiz are PLoS ONE Editorial Board members. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Funding: The present study was funded by the Consejo Superior de Deportes (grant #UPR12) Spanish Ministry of Science and Innovation (RYC-2010-05957) and Fondo de Investigaciones Sanitarias (ref. # PS09/00194), and grants from China Institute of Sport Science (Grant code: 2011-03) and grants from Ministry of Science and Technology of the People's Republic of China (Grant code: 2003BA904B04). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Eynon N, Ruiz JR, Oliveira J, Duarte JA, Birk R, et al. Genes and elite athletes: a roadmap for future research. J Physiol. 2011;589:3063–3070. doi: 10.1113/jphysiol.2011.207035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, et al. How to use an article about genetic association: B: Are the results of the study valid? JAMA. 2009;301:191–197. doi: 10.1001/jama.2008.946. [DOI] [PubMed] [Google Scholar]
  • 3.Bouchard C, Sarzynski MA, Rice TK, Kraus WE, Church TS, et al. Genomic predictors of the maximal O2 uptake response to standardized exercise training programs. J Appl Physiol. 2011;110:1160–1170. doi: 10.1152/japplphysiol.00973.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hall AM, Smith AJ, Bernlohr DA. Characterization of the Acyl-CoA synthetase activity of purified murine fatty acid transport protein 1. J Biol Chem. 2003;278:43008–43013. doi: 10.1074/jbc.M306575200. [DOI] [PubMed] [Google Scholar]
  • 5.Coleman RA, Lewin TM, Muoio DM. Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu Rev Nutr. 2000;20:77–103. doi: 10.1146/annurev.nutr.20.1.77. [DOI] [PubMed] [Google Scholar]
  • 6.Mashek DG, Li LO, Coleman RA. Rat long-chain acyl-CoA synthetase mRNA, protein, and activity vary in tissue distribution and in response to diet. J Lipid Res. 2006;47:2004–2010. doi: 10.1194/jlr.M600150-JLR200. [DOI] [PubMed] [Google Scholar]
  • 7.Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem. 1997;272:28210–28217. doi: 10.1074/jbc.272.45.28210. [DOI] [PubMed] [Google Scholar]
  • 8.Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907–925. [PubMed] [Google Scholar]
  • 9.Ellis JM, Li LO, Wu PC, Koves TR, Ilkayeva O, et al. Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab. 2010;12:53–64. doi: 10.1016/j.cmet.2010.05.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet. 2009;125:131–151. doi: 10.1007/s00439-008-0592-7. [DOI] [PubMed] [Google Scholar]
  • 11.Daniels J, Gilbert JR. Oxygen Power: Performance Tables for Distance Runners. Oxygen Power. 1979:5–15. [Google Scholar]
  • 12.Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, et al. Replicating genotype-phenotype associations. Nature. 2007;447:655–660. doi: 10.1038/447655a. [DOI] [PubMed] [Google Scholar]
  • 13.Black PN, DiRusso CC. Transmembrane movement of exogenous long-chain fatty acids: proteins, enzymes, and vectorial esterification. Microbiol Mol Biol Rev. 2003;67:454–472. doi: 10.1128/MMBR.67.3.454-472.2003. table of contents. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ellis JM, Mentock SM, Depetrillo MA, Koves TR, Sen S, et al. Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy. Mol Cell Biol. 2011;31:1252–1262. doi: 10.1128/MCB.01085-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001;107:813–822. doi: 10.1172/JCI10947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Phillips CM, Goumidi L, Bertrais S, Field MR, Cupples LA, et al. Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome. J Lipid Res. 2010;51:1793–1800. doi: 10.1194/jlr.M003046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mercado PA, Ayala YM, Romano M, Buratti E, Baralle FE. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res. 2005;33:6000–6010. doi: 10.1093/nar/gki897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sasabe T, Furukawa A, Matsusita S, Higuchi S, Ishiura S. Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients. Neurosci Lett. 2007;412:139–142. doi: 10.1016/j.neulet.2006.10.064. [DOI] [PubMed] [Google Scholar]
  • 19.Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331–1336. doi: 10.1126/science.1142358. [DOI] [PubMed] [Google Scholar]
  • 20.Knight JC. Regulatory polymorphisms underlying complex disease traits. J Mol Med. 2005;83:97–109. doi: 10.1007/s00109-004-0603-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.He ZH, Hu Y, Li YC, Yvert T, Santiago C, et al. Are calcineurin genes associated with athletic status? A function, replication study. Med Sci Sports Exerc. 2011;43:1433–1440. doi: 10.1249/MSS.0b013e31820e7f38. [DOI] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES